vimarsana.com
Home
Live Updates
Phase 3 KEYLYNK-008 Trial of Pembrolizumab Plus Olaparib in
Phase 3 KEYLYNK-008 Trial of Pembrolizumab Plus Olaparib in
Phase 3 KEYLYNK-008 Trial of Pembrolizumab Plus Olaparib in Metastatic Squamous NSCLC to Stop for Futility
The phase 3 KEYLYNK-008 trial evaluating pembrolizumab plus olaparib in patients with metastatic squamous non–small cell lung cancer will be discontinued for futility, according to an announcement from Merck.
Related Keywords
San Antonio ,
Texas ,
United States ,
,
Merck Research Laboratories ,
Antonio Breast Cancer Symposium ,
Keylynk 008 Trial ,
Nsclc ,
Pembrolizumab Plus Olaparib ,
Discontinued ,